H.R. 1344 · 116th Congress
Competitive DRUGS Act of 2019
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
DoggettSponsor21 cosponsors · 21 D
D
Blumenauer
EC
D
Cummings
JC
D
Chu
MC
D
Cartwright
RD
D
DeLauro
MD
D
DeSaulnier
RG
D
Grijalva
KH
D
Hill
MK
D
Kaptur
RK
D
Khanna
JL
D
Langevin
GM
D
Moore
EN
D
Norton
GN
D
Napolitano
AO
D
Ocasio-Cortez
CP
D
Pingree
MP
D
Pocan
MW
D
Waters
PW
D
Welch
JG
D
Garamendi
KP
D
Porter19 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 or the Competitive DRUGS Act of 2019
What it does: CRS summary · Introduced in House · Feb 25, 2019
Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 or the Competitive DRUGS Act of 2019
This bill authorizes the Federal Trade Commission to initiate a proceeding against parties to an agreement resolving or settling a patent infringement claim in connection with the sale of a drug.Such an agreement is generally presumed to be an unfair method of competition and is a violation of this bill if the filer of the generic drug application receives something of value and agrees to limit or forgo research, development, manufacturing, marketing, or sales of the generic drug.
However, an agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market the generic drug prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on a claim that the generic drug infringes a patent. An agreement if also exempt if the agreement's pro-competitive benefits outweigh its anticompetitive effects.
The bill establishes penalties for violations of the bill.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Competitive DRUGS Act of 2019
Also known as: Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019
Latest action (Mar 25, 2019): Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Policy area: Health · Origin: House · Introduced: Feb 25, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.